Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Acquired by Sector Gamma AS

Share on StockTwits

Sector Gamma AS lifted its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 34.8% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 96,900 shares of the biopharmaceutical company’s stock after acquiring an additional 25,000 shares during the period. Alnylam Pharmaceuticals accounts for approximately 1.3% of Sector Gamma AS’s investment portfolio, making the stock its 28th biggest holding. Sector Gamma AS’s holdings in Alnylam Pharmaceuticals were worth $7,793,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of ALNY. State of Alaska Department of Revenue grew its stake in Alnylam Pharmaceuticals by 1.4% during the 2nd quarter. State of Alaska Department of Revenue now owns 11,061 shares of the biopharmaceutical company’s stock worth $802,000 after buying an additional 152 shares during the last quarter. World Asset Management Inc grew its stake in Alnylam Pharmaceuticals by 6.0% during the 2nd quarter. World Asset Management Inc now owns 3,190 shares of the biopharmaceutical company’s stock worth $231,000 after buying an additional 180 shares during the last quarter. US Bancorp DE grew its stake in Alnylam Pharmaceuticals by 70.2% during the 2nd quarter. US Bancorp DE now owns 628 shares of the biopharmaceutical company’s stock worth $46,000 after buying an additional 259 shares during the last quarter. Quadrant Capital Group LLC grew its stake in Alnylam Pharmaceuticals by 66.7% during the 3rd quarter. Quadrant Capital Group LLC now owns 720 shares of the biopharmaceutical company’s stock worth $56,000 after buying an additional 288 shares during the last quarter. Finally, United Services Automobile Association grew its stake in Alnylam Pharmaceuticals by 0.7% during the 2nd quarter. United Services Automobile Association now owns 50,033 shares of the biopharmaceutical company’s stock worth $3,630,000 after buying an additional 330 shares during the last quarter. 93.95% of the stock is currently owned by institutional investors and hedge funds.

A number of research analysts recently issued reports on the company. Needham & Company LLC restated a “buy” rating and set a $135.00 price target on shares of Alnylam Pharmaceuticals in a research note on Thursday, October 31st. Stifel Nicolaus set a $116.00 target price on Alnylam Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, September 3rd. Zacks Investment Research downgraded Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating and set a $93.00 target price on the stock. in a research note on Wednesday, September 18th. UBS Group lifted their target price on Alnylam Pharmaceuticals from $95.00 to $96.00 and gave the company a “neutral” rating in a research note on Wednesday, September 4th. Finally, Morgan Stanley lowered their target price on Alnylam Pharmaceuticals from $126.00 to $124.00 and set an “overweight” rating on the stock in a research note on Wednesday, August 7th. One analyst has rated the stock with a sell rating, five have issued a hold rating and thirteen have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $111.59.

Shares of ALNY stock traded up $1.49 during midday trading on Friday, hitting $93.03. The company had a trading volume of 536,500 shares, compared to its average volume of 804,622. Alnylam Pharmaceuticals, Inc. has a 52-week low of $60.27 and a 52-week high of $96.08. The stock has a market cap of $10.26 billion, a price-to-earnings ratio of -12.29 and a beta of 2.37. The company’s 50 day simple moving average is $84.12 and its 200 day simple moving average is $77.94. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.38 and a quick ratio of 5.22.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.92) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($2.17) by $0.25. Alnylam Pharmaceuticals had a negative return on equity of 52.88% and a negative net margin of 485.73%. The company had revenue of $70.06 million during the quarter, compared to analysts’ expectations of $57.14 million. During the same period in the previous year, the firm posted ($1.56) earnings per share. The business’s revenue for the quarter was up 3284.5% compared to the same quarter last year. Analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -7.89 EPS for the current year.

In other news, CEO John Maraganore sold 49,456 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, October 14th. The stock was sold at an average price of $79.45, for a total value of $3,929,279.20. Following the completion of the sale, the chief executive officer now owns 239,449 shares of the company’s stock, valued at $19,024,223.05. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, President Barry E. Greene sold 58,913 shares of Alnylam Pharmaceuticals stock in a transaction on Tuesday, October 22nd. The shares were sold at an average price of $89.99, for a total value of $5,301,580.87. Following the completion of the sale, the president now directly owns 111,851 shares of the company’s stock, valued at approximately $10,065,471.49. The disclosure for this sale can be found here. Insiders own 3.60% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases.

Featured Article: Understanding Compound Annual Growth Rate (CAGR)

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.